News for Healthier Living

PI3K-Driven Wild-Type RAS Activation Fuels KRAS Inhibitor Resistance

This study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.

May 31, 2026


May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026

May 20 2026

May 19 2026

May 18 2026

May 17 2026